EMPA-KIDNEY: Among a wide range of patients w/ CKD who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from CV causes (vs. placebo) ca. 2022 from @NEJM #KidneyWk #Nephpearls 👉🏼 nejm.org/doi/full/10.1056/NE…

@jmdnephdoc doing what he does best at #KidneyWk. Great talk on Hepatorenal Syndrome and kidney injury markers. It’s good to know there is still some value in calculating FeNa. @YaleNephrology @brewster_ursula @virmani_sar

Watch out world, @YaleNephrology is taking on POCUS!!! Hands on faculty training session with @Yale_EUS and @cmoore433 today in the Yale Sim Lab!!! @Nephronette was inspiring all of us with her skills.